Advanced Filters
noise

Baltimore, Maryland Clinical Trials

A listing of Baltimore, Maryland clinical trials actively recruiting patient volunteers.

Found 826 clinical trials
J Jonathan Jun, MD

Dinner Time for Obesity and Prediabetes

Obesity and its metabolic complications are leading causes of global morbidity and mortality. Evidence is mounting that inappropriate timing of food intake contributes to obesity. Specifically, late eating is associated with greater weight gain and metabolic syndrome. However, the mechanism by which late eating harms metabolism is not fully understood …

18 - 50 years of age All Phase N/A
O Odessa R Addison, PhD DPT

Reducing Fall Risk With NMES

Falls are dangerous leading to injuries, hospital admissions and even death. Fall prevention is a priority but effective programs only reduce falls by 30%. Weak hip muscles may be one reasons individuals experience a loss of balance. However individuals who have weak hip muscles may be unable to exercise at …

55 years of age All Phase N/A
L Laura Retson, MD

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth …

years of age All Phase 2
T Taylor Stephenson, RN

Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer

A Phase 1/2a, open-label, multicenter study of intramuscular (i.m.) PRL-02 depot in participants with advanced prostate cancer.

18 years of age Male Phase 1/2
S Steven R Zeiler, MD, PhD

Self-Administered Gaming and Exercise at Home (SAGEH)

This study aims at comparing manual function outcomes between the standard of care and additional self-administered hand therapy after stroke. Strokes are common neurological injuries, and although rates of survival have increased in recent decades, survivors often continue to experience deficiencies in hand dexterity and bimanual function. Most motor recovery …

21 years of age All Phase N/A
A Aliza Gardenswartz

Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

This research is being done to find out if an investigational drug, Nivolumab, can be safely administered after a "half-matched" (haplo) bone marrow transplant (BMT), and if the investigational drug will help to prevent or delay relapse or progression of sarcomas. In this study investigators will also be trying to …

12 - 40 years of age All Phase 1/2
L Lorenzo Leggio, M.D.

Spironolactone in Alcohol Use Disorder (SAUD)

Background Alcohol use disorder (AUD) affects about 29.5 million people in the United States. Only 3 medicines have been approved by Food and Drug Administration to treat AUD. Researchers want to find better treatments for AUD. Animal studies found that a medicine called spironolactone, may decrease the amount of alcohol …

21 - 99 years of age All Phase 1
S Samantha Horn

Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)

The purpose of this study is to evaluate the effect of atorvastatin on brain vessel reactivity and with it on blood flow in people with mild cognitive impairment.

60 - 95 years of age All Phase 2
T Tracy Waasdorp, Ph.D.

Coaching Teachers in Bullying Detection and Intervention

The investigators' overall objective is to demonstrate the efficacy of the Bullying Classroom Check-Up (BCCU) on elementary aged students' aggressive and bullying behaviors, teacher practices, and student and teacher relationships. The investigators' principal hypothesis is that the BCCU will improve students' aggression and bullying behaviors and their perceptions of the …

8 - 99 years of age All Phase N/A

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).

18 years of age All Phase 1

Simplify language using AI